Fennec Pharmaceuticals Inc. (FENCF) 2.8570 $FENCF
Fennec Pharmaceuticals Announces That the Independent Data Monitoring Committee (IDMC) Recommends the Continuation of SIOPEL 6 Phase 3 Clinical Trial
Marketwired - Mon Feb 02, 7:02AM CST
Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF), a company focused on the development of sodium thiosulfate (STS) for the prevention of ototoxicity from cisplatin in pediatric patients, announced that the IDMC overseeing the SIOPEL 6 phase 3 clinical trial recommended that the study be continued as planned. The IDMC has been established to assess any potential concern of an adverse effect of STS on the efficacy of the cisplatin chemotherapy and to review safety according to protocol pre-specified patient numbers. Previously, the IDMC reached similar conclusion after reviewing the safety of 20, 40, 60 and 80 patients and their current recommendation on 100 patients to continue the clinical trial represents the last and final safety review.
FRX.TO: 3.55 (+0.16)
Fennec Pharmaceuticals Announces Completion of Patient Enrollment in Sodium Thiosulfate Phase 3 SIOPEL 6 Study
Marketwired - Mon Jan 05, 8:03AM CST
Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF), today reported the second sodium thiosulfate Phase 3 study, conducted by the International Childhood Liver Tumour Strategy Group, SIOPEL 6, has fully enrolled and is now closed for recruitment. One hundred and sixteen patients in 46 clinical centers from 12 countries participated in the study.
FRX.TO: 3.55 (+0.16)
Fennec Announces Private Placement of Units
Marketwired - Wed Dec 03, 8:44AM CST
Fennec Pharmaceuticals Inc. (the "Company" or "Fennec"
(TSX: FRX)(OTCQB: FENCF), announced today that it has completed a non-brokered private placement (the "Offering" of 732,266 units for gross proceeds of US$2,196,798.
FRX.TO: 3.55 (+0.16)
Fennec Pharmaceuticals Provides Corporate Update and Third Quarter Ended September 30, 2014 Financial Results
Marketwired - Thu Nov 13, 4:29PM CST
Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF) today reported its financial results and recent developments for the third quarter ended September 30, 2014. All amounts are in US dollars unless otherwise specified.
FRX.TO: 3.55 (+0.16)
Fennec Pharmaceuticals Announces That the Independent Data Monitoring Committee (IDMC) Recommends the Continuation of SIOPEL 6 Phase 3 Clinical Trial
Marketwired - Mon Feb 02, 7:02AM CST
Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF), a company focused on the development of sodium thiosulfate (STS) for the prevention of ototoxicity from cisplatin in pediatric patients, announced that the IDMC overseeing the SIOPEL 6 phase 3 clinical trial recommended that the study be continued as planned. The IDMC has been established to assess any potential concern of an adverse effect of STS on the efficacy of the cisplatin chemotherapy and to review safety according to protocol pre-specified patient numbers. Previously, the IDMC reached similar conclusion after reviewing the safety of 20, 40, 60 and 80 patients and their current recommendation on 100 patients to continue the clinical trial represents the last and final safety review.
FRX.TO: 3.55 (+0.16)
Fennec Pharmaceuticals Announces Completion of Patient Enrollment in Sodium Thiosulfate Phase 3 SIOPEL 6 Study
Marketwired - Mon Jan 05, 8:03AM CST
Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF), today reported the second sodium thiosulfate Phase 3 study, conducted by the International Childhood Liver Tumour Strategy Group, SIOPEL 6, has fully enrolled and is now closed for recruitment. One hundred and sixteen patients in 46 clinical centers from 12 countries participated in the study.
FRX.TO: 3.55 (+0.16)
Fennec Announces Private Placement of Units
Marketwired - Wed Dec 03, 8:44AM CST
Fennec Pharmaceuticals Inc. (the "Company" or "Fennec"
(TSX: FRX)(OTCQB: FENCF), announced today that it has completed a non-brokered private placement (the "Offering" of 732,266 units for gross proceeds of US$2,196,798. FRX.TO: 3.55 (+0.16)
Fennec Pharmaceuticals Provides Corporate Update and Third Quarter Ended September 30, 2014 Financial Results
Marketwired - Thu Nov 13, 4:29PM CST
Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF) today reported its financial results and recent developments for the third quarter ended September 30, 2014. All amounts are in US dollars unless otherwise specified.
FRX.TO: 3.55 (+0.16)
